Articles

How Does Dalton Venture Precisely Capture Investment Growth Opportunities by Focusing on Cardiovascular Disease Diagnosis, Treatment, and Management? | Dalton Insights

How Does Dalton Venture Precisely Capture Investment Growth Opportunities by Focusing on Cardiovascular Disease Diagnosis, Treatment, and Management? | Dalton Insights

For decades, cardiovascular disease has been considered the "leading killer" threatening global human health and longevity, with mortality rates reaching 5% among patients over 65. As population aging accelerates and lifestyles shift, the prevalence of chronic heart conditions is rising markedly — spurring waves of innovation across cardiovascular device segments to address persistent treatment pain points and improve diagnostic and therapeutic efficiency and safety.

Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident

Qiming Venture Partners' Kan Chen: AI's Transformation of Biomedicine Is Already Evident

In the AI era, drug discovery is taking on the characteristics of data-driven, high-throughput, automated, and intelligent processes, potentially improving success rates and lowering costs. In the near term, the necessity of experimental validation will remain unchanged; over the long run, the foundational theories of biology will stay stable. This balance between transformation and continuity is reshaping the entire landscape of pharmaceutical R&D.

Morning Star | Jieti Medical: The Value of Brain-Computer Interfaces Is Greater Than Imagined, Aiming to Rival Elon Musk's Neuralink

Morning Star | Jieti Medical: The Value of Brain-Computer Interfaces Is Greater Than Imagined, Aiming to Rival Elon Musk's Neuralink

To capture this hundred-billion-yuan brain-computer interface market, system development must be application-value driven, implemented according to clinical standards, and ultimately achieve commercialization.